Anti-IL-17α (Netakimab), Human IgG1 Antibody

Anti-IL-17α (Netakimab), Human IgG1 Antibodyis available at Gentaur for Next week Delivery.

Description: The research-grade biosimilar is a humanized IgG1 monoclonal antibody that targets IL-17α and prevents the interaction with its receptor (IL-17R), thus blocking IL-17α mediated inflammatory and immune responses. IL-17α is a pro-inflammatory cytokine that plays an important role in inflammatory diseases such as psoriatic arthritis and ankylosing spondylitis (AS). In the heavy chain of the original antibody, VH variable domain is replaced with the VHH domain of Lama glama that possesses a long complementary determining region (CDR-H3) that allows the antibody to bind IL-17 with a higher affinity. The original antibody-drug has been approved to treat moderate-to-severe plaque psoriasis. Additionally, the drug is undergoing clinical trials to treat ankylosing spondylitis (AS).

Immunogen Sequence:Human IL-17α

Target Alternative Name:BCD-085, BCD085, BCD 085, IL17a, IL17, CTLA8, IL-17, CTLA-8, IL-17A

Species Reactivities:/

Tag Line:The biosimilar is a humanized monoclonal antibody that targets IL-17α and inhibits IL-17α mediated inflammatory responses

Formulation:In PBS, pH 7.5

Purification: Protein A purified

Application:/

Positive Control:/

Application And Usages:/

Handling:The antibody solution should be gently mixed before use.